Anti-Cytosolic 5'-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study.
autoantibodies
idiopathic inflammatory myopathies
inclusion body myositis
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
12 Jul 2023
12 Jul 2023
Historique:
received:
07
06
2023
revised:
04
07
2023
accepted:
10
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Anti-cytosolic 5'-nucleotidase 1A (anti-cN1A) antibodies were proposed as a biomarker for the diagnosis of inclusion body myositis (IBM), but conflicting specificity and sensitivity evidence limits its use. Our study aimed to assess the diagnostic accuracy of anti-cN1A in a cohort of patients who underwent a myositis line immunoassay for suspected idiopathic inflammatory myopathies (IIM). We also assessed the agreement between two testing procedures: line immunoassay (LIA) and enzyme-linked immunoassay (ELISA). We collected retrospective clinical and serological data for 340 patients who underwent a myositis antibody assay using LIA (EUROLINE Autoimmune Inflammatory Myopathies 16 Ag et cN-1A (IgG) line immunoassay) and verification with an anti-cN1A antibody assay using ELISA (IgG) (Euroimmun Lubeck, Germany). The serum samples of 20 (5.88%) patients (15 females, 5 males, mean age 58.76 ± 18.31) tested positive for anti-cN1A using LIA, but only two out of twenty were diagnosed with IBM. Seventeen out of twenty tested positive for anti-cN1A using ELISA (median IQR, 2.9 (1.9-4.18)). Our study suggests excellent concordance between LIA and ELISA for detecting anti-cN1A antibodies. LIA may be a rapid and useful adjunct, and it could even replace ELISA for cN1A assay. However, the high prevalence of diseases other than IBM in our cohort of anti-cN1A-positive patients did not allow us to consider anti-cN1A antibodies as a specific biomarker for IBM.
Sections du résumé
BACKGROUND
BACKGROUND
Anti-cytosolic 5'-nucleotidase 1A (anti-cN1A) antibodies were proposed as a biomarker for the diagnosis of inclusion body myositis (IBM), but conflicting specificity and sensitivity evidence limits its use. Our study aimed to assess the diagnostic accuracy of anti-cN1A in a cohort of patients who underwent a myositis line immunoassay for suspected idiopathic inflammatory myopathies (IIM). We also assessed the agreement between two testing procedures: line immunoassay (LIA) and enzyme-linked immunoassay (ELISA).
MATERIALS AND METHODS
METHODS
We collected retrospective clinical and serological data for 340 patients who underwent a myositis antibody assay using LIA (EUROLINE Autoimmune Inflammatory Myopathies 16 Ag et cN-1A (IgG) line immunoassay) and verification with an anti-cN1A antibody assay using ELISA (IgG) (Euroimmun Lubeck, Germany).
RESULTS
RESULTS
The serum samples of 20 (5.88%) patients (15 females, 5 males, mean age 58.76 ± 18.31) tested positive for anti-cN1A using LIA, but only two out of twenty were diagnosed with IBM. Seventeen out of twenty tested positive for anti-cN1A using ELISA (median IQR, 2.9 (1.9-4.18)).
CONCLUSIONS
CONCLUSIONS
Our study suggests excellent concordance between LIA and ELISA for detecting anti-cN1A antibodies. LIA may be a rapid and useful adjunct, and it could even replace ELISA for cN1A assay. However, the high prevalence of diseases other than IBM in our cohort of anti-cN1A-positive patients did not allow us to consider anti-cN1A antibodies as a specific biomarker for IBM.
Identifiants
pubmed: 37509600
pii: biomedicines11071963
doi: 10.3390/biomedicines11071963
pmc: PMC10377506
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Neuromuscul Dis. 2021 Sep 1;23(1):31-38
pubmed: 34431799
Ann Neurol. 2013 Mar;73(3):408-18
pubmed: 23596012
Front Immunol. 2018 Jun 05;9:1200
pubmed: 29922285
Nat Rev Rheumatol. 2019 May;15(5):257-272
pubmed: 30837708
Muscle Nerve. 2021 Apr;63(4):490-496
pubmed: 33373040
Arthritis Rheumatol. 2019 Sep;71(9):1400-1412
pubmed: 31385462
Eur Respir Rev. 2015 Jun;24(136):216-38
pubmed: 26028634
J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):373-8
pubmed: 25857661
Rheumatology (Oxford). 2022 May 30;61(6):2504-2511
pubmed: 34617994
Arthritis Rheumatol. 2017 Jan;69(1):35-45
pubmed: 27785888
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Cells. 2021 May 10;10(5):
pubmed: 34068623
Neuromuscul Disord. 2013 Dec;23(12):1044-55
pubmed: 24268584
Ann Rheum Dis. 2016 Apr;75(4):696-701
pubmed: 25714931
Neurology. 1994 Jun;44(6):1131-7
pubmed: 7516055
Auto Immun Highlights. 2016 Dec;7(1):16
pubmed: 27858337
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Autoimmun Rev. 2019 Mar;18(3):293-305
pubmed: 30639643
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):326
pubmed: 32573418
Clin Exp Rheumatol. 2022 Feb;40(2):384-393
pubmed: 35225226
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
J Clin Med. 2020 Sep 11;9(9):
pubmed: 32933078